Serum Markers of Collagen Turnover Predict Future Shocks in Implantable Cardioverter-Defibrillator Recipients With Dilated Cardiomyopathy on Optimal Treatment  by Kanoupakis, Emmanuel M. et al.
D
t
d
u
(
t
t
p
F
U
M
2
Journal of the American College of Cardiology Vol. 55, No. 24, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
PSerum Markers of Collagen Turnover
Predict Future Shocks in Implantable
Cardioverter-Defibrillator Recipients With
Dilated Cardiomyopathy on Optimal Treatment
Emmanuel M. Kanoupakis, MD,* Emmanuel G. Manios, MD,* Eleftherios M. Kallergis, MD,*
Hercules E. Mavrakis, MD,* Christos A. Goudis, MD,* Ilias G. Saloustros, MD,*
Maria E. Milathianaki, MD,† Gregory I. Chlouverakis, PHD,‡ Panos E. Vardas, MD, PHD*
Crete, Greece
Objectives We investigated prospectively whether serum markers of collagen turnover could be used as predictors for the
occurrence of malignant ventricular arrhythmias in patients with nonischemic dilated cardiomyopathy (NIDC)
who had received an implantable cardioverter-defibrillator (ICD) for primary prevention.
Background Extracellular matrix alterations in NIDC might provide electrical heterogeneity, thus potentially contributing to
the occurrence of ventricular arrhythmia and subsequent sudden cardiac death (SCD).
Methods Serum C-terminal propeptide of collagen type-I, C-terminal telopeptide of collagen type-I, matrix metalloprotein-
ase (MMP)-1, and tissue inhibitor of MMP-1 were measured as markers of collagen synthesis and degradation in
70 patients with mild to moderate symptomatic heart failure due to NIDC with left ventricular ejection fraction
35%, who received an ICD for primary prevention of SCD. Patients were evaluated for any appropriate ICD de-
livered therapy, whether shock or antitachycardia pacing, during a 1-year follow-up period.
Results Appropriate device therapies were delivered in 14 of the 70 patients during the follow-up period, with antitachy-
cardia pacing in 2, antitachycardia pacing with shocks in 4, and shocks in 8. Pre-implantation serum concentra-
tions of C-terminal telopeptide of collagen type-I levels were significantly higher in patients who had appropriate
ICD-delivered therapy than in those who did not have any therapy (0.46  0.19 ng/ml vs. 0.19  0.07 ng/ml,
p  0.001, respectively). The same was true for baseline MMP-1 and tissue inhibitor of MMP-1 (27.7  1.6
ng/ml vs. 24.1  2.5 ng/ml, p  0.001, and 89  14 ng/ml vs. 58  18 ng/ml, p  0.008, respectively).
Conclusions If the maximum benefit is to be achieved from ICD therapy in NIDC patients for the primary prevention of SCD, a
more precise risk stratification is required. As extracellular matrix alterations affect the arrhythmogenic sub-
strate in NIDC, we observed that serum markers of collagen turnover could predict arrhythmic events in ICD
recipients. (J Am Coll Cardiol 2010;55:2753–9) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.040b
e
s
H
t
h
p
p
a
ruring the last few years, several trials have been published
hat showed a survival benefit for implantable cardioverter-
efibrillator (ICD) therapy over antiarrhythmic drugs alone,
sed for the primary prevention of sudden cardiac death
SCD) in patients with nonischemic dilated cardiomyopa-
hy (NIDC) (1–4). Therefore, according to these trials ICD
herapy should be considered in these patients. In recent
ractice guidelines, ICD insertion in patients with NIDC is
rom the *Department of Cardiology and †Laboratory of Biochemistry, Heraklion
niversity Hospital, Crete, Greece; and the ‡Biostatistics Laboratory, Faculty of
edicine, University of Crete, Crete, Greece.w
Manuscript received October 15, 2009; revised manuscript received February 19,
010, accepted February 25, 2010.ased only on the degree of left ventricular dysfunction, as
stimated by the ejection fraction, and on the functional
tage of congestive heart failure quantified by New York
eart Association (NYHA) functional class (5). However,
he discussion continues, largely because it is still not clear
See page 2760
ow the selection of patients could be optimized. To
rovide the maximum benefit from ICD therapy, individual
rediction is required to discriminate between patients who
re at increased risk for SCD and those with a negligible
isk, who would be exposed to potential adverse effects
ithout benefit. With this in mind, it would be highly
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clinical or laboratory indexes that
reflect the arrhythmia substrate
and might better identify pa-
tients at risk as early as possible.
It is known that the remodel-
ing process in NIDC is charac-
terized by changes in extracellu-
lar matrix (ECM), including
fibrosis formation and collagen
degradation (6–8). The ECM
alterations might provide electri-
cal heterogeneity, which is an
appropriate substrate for arrhyth-
mogenesis, thus potentially con-
tributing to the occurrence of
ventricular arrhythmia and sub-
sequent SCD (9). Experimental
and clinical data suggest that
biochemical markers of collagen
turnover correlate significantly
with fibrosis in endomyocardial
biopsies in hypertensive patients
(10). Serological markers of these
processes seem to be important
targets of therapy and have been
used to provide information
bout prognosis in patients with symptomatic heart failure
11) and idiopathic or ischemic dilated cardiomyopathies
12) and after acute myocardial infarction (13).
In this study we planned to investigate prospectively
hether serum markers of collagen turnover could be used
s predictors for the occurrence of malignant ventricular
rrhythmias in patients with NIDC who have received an
CD insertion for primary prevention.
ethods
atient selection. The ethics committee of our institution
pproved the study. This investigation conforms to the
rinciples outlined in the Declaration of Helsinki. Signed
nformed written consent was obtained from all subjects
efore their participation in the study.
The study population consisted of 70 patients with
IDC, who had either attended or been referred to our
linic, the only tertiary cardiology care center on the island,
or evaluation and ICD insertion. All patients had NYHA
unctional class II to III heart failure, a left ventricular
jection fraction (LVEF) 35%, a documented nonsus-
ained ventricular tachycardia (VT) on Holter monitoring,
nd/or inducible sustained ventricular tachyarrhythmia dur-
ng programmed ventricular stimulation, and an ICD was
nserted for the first time for primary prevention of SCD.
The original diagnosis of NIDC was based on typical
chocardiographic features and was defined as left ventric-
Abbreviations
and Acronyms
CICP  C-terminal
propeptide of collagen
type-I
CITP  C-terminal
telopeptide of collagen
type-I
ECM  extracellular matrix
ICD  implantable
cardioverter-defibrillator
LVEF  left ventricular
ejection fraction
MMP  matrix
metalloproteinase
NIDC  nonischemic
dilated cardiomyopathy
NYHA  New York Heart
Association
SCD  sudden cardiac
death
TIMP  tissue inhibitor of
matrix metalloproteinases
VF  ventricular fibrillation
VT  ventricular
tachycardialar end-diastolic diameter (LVEDD) 55 mm with iVEF 35%. All patients underwent coronary angiogra-
hy, and those with epicardial coronary artery disease or
ther secondary NIDC were excluded from this study.
ctive myocarditis, recently (9 months) diagnosed
IDC, or decompensated heart failure constituted an ex-
lusion criterion. Furthermore, conditions known to alter
ollagen turnover, such as liver disease, renal impairment,
ulmonary fibrosis, extensive wounds, metabolic bone dis-
ase, malignancy, connective tissue disorders, chronic in-
ammatory disease, ongoing treatment with corticosteroids,
nd recent infection or surgery, were all considered exclu-
ion criteria.
The patients were clinically stabilized by treatment with a
ombination of aldosterone antagonists, angiotensin-
onverting enzyme inhibitors, or angiotensin II receptor
lockers and carvedilol.
tudy design. BIOCHEMICAL MEASUREMENTS OF MARKERS
F COLLAGEN TURNOVER. Because collagen type-I is the
ajor collagenous product of cardiac fibroblasts (14), we
sed as markers of collagen turnover serum peptides derived
rom the tissue synthesis (C-terminal propeptide of collagen
ype-I [CICP]) and degradation (C-terminal telopeptide of
ollagen type-I [CITP]) of collagen type-I (10). Enzymes
hat control collagen type-I turnover, specifically matrix
etalloproteinase (MMP)-1 and tissue inhibitor of matrix
etalloproteinases (TIMP)-1, were also measured (15).
Blood samples were obtained at the beginning of the
tudy, before placement of the ICD, by direct puncture of
n antecubital vein after 30 min of supine rest, and were
mmediately placed on ice and centrifuged within 1 h.
pecimens were stored at 80°C until analysis.
The CICP levels were determined by a sandwich enzyme
mmunoassay with a commercially available kit (enzyme
mmunoassay, Metra CICP, Quidel, San Diego, Califor-
ia), whereas CITP was measured with the Elecsys beta-
rossLaps/serum assay (Roche Diagnostics, Mannheim,
ermany). Serum MMP-1 and TIMP-1 levels were as-
ayed by enzyme-linked immunoadsorbent assay with com-
ercially available kits (Human Biotrack enzyme-linked
mmunoadsorbent assay system, Amersham Biosciences,
iscataway, New Jersey). Measurements were performed in
uplicate by personnel blinded to the patients’ clinical
etails. The intra- and inter-assay coefficients of variation of
ll assays were 8% and 10%, respectively, in our labo-
atory.
EVICE FOLLOW-UP AND DATA COLLECTION. After im-
lantation, a complete evaluation of device function was
erformed, and the tachycardia therapies and detection rates
ere programmed. A VT detection zone with antitachycar-
ia pacing therapy was programmed in all patients, followed
y shocks if necessary. Above 200 beats/min, only shock
herapies were programmed. All patients were followed-up
n the implantable device clinic of our department every 3
onths or sooner in cases of device discharges, thus ensur-
ng comprehensive data collection.
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June 15, 2010:2753–9 Collagen Turnover and Ventricular ArrhythmiasData concerning arrhythmias and device therapy were
btained and stored at the time of device interrogation on
ach follow-up visit. The incidence and type of arrhythmias
nd the incidence of appropriate and inappropriate defibril-
ator therapies were determined by reviewing stored elec-
rograms. Events were classified by an agreement of 2
eviewing electrophysiologists blinded to the study. Ventric-
lar tachyarrhythmias were categorized as VT or ventricular
brillation (VF) on the basis of rate and morphology and by
he type of device therapy (antitachycardia pacing or shock)
hat terminated the tachyarrhythmia. Appropriate antitachy-
ardia pacing or shock was defined as any ICD therapy that
ccurred in response to VT or VF, whereas such an event was
lassified as inappropriate when it was triggered by supraven-
ricular tachycardias or T-wave oversensing or when it was
econdary to electrode dysfunction.
On each visit, an appropriate clinical and laboratory
valuation, which included cardiac troponins, plasma elec-
rolytes, and thyroid hormones to exclude factors potentially
riggering arrhythmias, was carried out. Medication use was
lso recorded.
The end point of the study was the occurrence of any
ppropriate ICD delivered therapy, whether shock or anti-
achycardia pacing, for malignant ventricular arrhythmias
uring a 1-year follow-up period.
tatistical analysis. Summary descriptive data are pre-
ented as mean  SD for continuous variables and counts
proportions) for categorical variables. Patients were classi-
ed into 2 groups: group I included patients who experi-
nced at least 1 VT during the study period, and group II
ncluded patients without VT during the study period.
Categorical variables were compared between groups
ith a Pearson chi-square test or a Fisher exact test (when
hi-square was not applicable). Continuous variables were
ompared with a t test or a Mann-Whitney U test, as
ppropriate. Receiver-operating characteristic curves show-
ng the diagnostic performance of serum markers were
onstructed. The association between continuous parame-
ers was assessed with Pearson’s correlation coefficient. A
tepwise logistic regression model was employed to explore
he potential impact of significant predictors for shocks.
alues of p  0.05 were considered statistically significant.
he software SPSS version 17 (SPSS Inc., Chicago, Illi-
ois) was used for our analysis.
esults
aseline characteristics. The patient population included
2 women and 58 men, ranging in age from 41 to 77 years.
hirty-seven patients were classified as NYHA functional
lass II, and 33 were classified as NYHA functional class III.
he mean LVEF was 25.1  7%, and the mean LVEDD
as 60.4  6 mm. Patients were receiving optimal medical
herapy for NICM, which included carvedilol, angiotensin-
onverting enzyme inhibitors, angiotensin II receptor block-
rs, or aldosterone antagonists, unless there was any contra-
c
endication or patient intolerance. Digoxin and diuretics were
sed when necessary to manage clinical symptoms.
linical outcome and collagen turnover levels. All pa-
ients underwent their routine follow-up examination, none
ithdrew, and no patient died during the study period.
ppropriate device therapies were delivered in 14 of the 70
atients during the 1-year follow-up period, with antitachy-
ardia pacing in 2, antitachycardia pacing with shocks in 4,
nd shocks in 8.
The initial arrhythmia triggering defibrillator activity was
onomorphic VT in 9 patients and VF in 5 patients.
mong these 14 patients, 8 patients had 1 tachyarrhythmic
vent, and the remaining 6 had 2 or more episodes.
Apart from the 14 patients who experienced appropriate
evice therapies, 3 patients experienced inappropriate ICD
ischarge due to atrial fibrillation.
Table 1 presents the baseline characteristics of patients
ith and without appropriate ICD-delivered therapy. Age,
ex, NYHA functional class, LVEF, LVEDD, and medi-
ations did not differ between these 2 groups. No difference
as observed between the 2 groups with regard to the
resence of diabetes mellitus or atrial fibrillation and kidney
isease or the dosage of carvedilol. There was no difference
etween the groups with regard to the selection criterion for
evice implantation (i.e., if patients had nonsustained VT
n Holter monitoring or VT induction during programmed
entricular stimulation) (p  0.99). For CICP levels the
ifference between the 2 groups was not significant (56.7 
4 ng/ml vs. 56.2  12 ng/ml, p  0.90).
Pre-implantation serum concentrations of CITP levels
ere significantly higher in patients who had appropriate
CD-delivered therapy than in those who did not have any
herapy (0.46  0.19 ng/ml vs. 0.19  0.07 ng/ml, p 
.001, respectively) (Fig. 1). The same was true for baseline
MP-1 and TIMP-1 (27.7  1.6 ng/ml vs. 24.1  2.5
aseline Characteristics of Patients Whoid and Did Not Rece ve Ther py From an ICDTable 1 B seline Characteristics of Patients WhoDid and Did Not Receive Therapy From an ICD
ICD Therapy
(n  14)
No ICD Therapy
(n  56) p Value
Age (yrs) 65 21 65 25 0.99
Men 12 (86%) 45 (80%) 0.95
NYHA functional class II 8 (57%) 29 (52%) 0.77
NYHA functional class III 6 (43%) 27 (48%) 0.77
LVEF (%) 23 4 25 7 0.27
LVEDD (mm) 61 5 60 6 0.30
Atrial fibrillation 2 (14%) 12 (16%) 0.99
Diabetes mellitus 4 (28%) 13 (23%) 0.73
Kidney disease 1 (7%) 13 (9%) 0.99
ACE inhibitors or ATII blockers 13 (93%) 54 (96%) 0.49
Carvedilol 14 (100%) 55 (98%) 0.99
Dosage of carvedilol (mg/day) 24.5 18 23.6 16 0.85
Aldosterone antagonists 11 (78%) 43 (76%) 0.99
ata are expressed as mean  SD or n (%) unless otherwise noted. None of the differences
etween groups were statistically significant.
ACE  angiotensin converting enzyme; ATII  angiotensin II receptor; ICD  implantableardioverter-defibrillator; LVEDD  left ventricular end-diastolic diameter; LVEF  left ventricular
jection fraction; NYHA  New York Heart Association.
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Collagen Turnover and Ventricular Arrhythmias June 15, 2010:2753–9g/ml, p  0.001, and 89  14 ng/ml vs. 58  18 ng/ml,
 0.008, respectively) (Figs. 2 and 3). To compare the
forementioned 3 markers in terms of their sensitivity and
pecificity we constructed receiver-operating characteristic
urves. As can be seen in Figure 4 CITP perform better
Figure 1 Box Plot Depiction of the
Differences in Levels of Serum CITP
Pre-implantation C-terminal telopeptide of collagen type-I (CITP) concentrations
were significantly higher in patients more prone to malignant arrhythmias.
Boxes represent the middle one-half of the distribution (25th to 75th percen-
tile). The line in a box is the median. The solid circle represents the mild out-
lier (between 1.5  interquartile range [IQR] and 3  IQR away from quartiles).
ICD  implantable cardioverter-defibrillator.
Figure 2 Box Plot of Serum Concentrations of MMP-1
Baseline matrix metalloproteinase (MMP)-1 levels were significantly higher in
patients who had appropriate ICD-delivered therapy than in those who did not
have any therapy. Boxes represent the middle one-half of the distribution (25th
to 75th percentile). The line in a box is the median. The solid circle repre-
sents the mild outlier (between 1.5  IQR and 3  IQR away from quartiles).
Abbreviations as in Figure 1.han the other 2 markers. More specifically the area under
he curve for CITP, MMP-1, TIMP-1 is 0.95, 0.883, and
.782, respectively. Moreover a CITP cutoff point of 0.28
g/ml was found to be 85.7% sensitive and 89.3% specific
or the prediction of malignant arrhythmic events. Similarly
n MMP-1 cutoff value of 26 ng/ml yields 78.6% sensitivity
nd 81% specificity. For TIMP-1 a cutoff point of 45 ng/ml
ad 85.7% sensitivity and 60.7% specificity for the occur-
ence of ventricular arrhythmias that require appropriate
CD-delivered therapy.
Figure 3 Pre-Implantation Serum Concentrations of TIMP-1
Serum levels of tissue inhibitor of matrix metalloproteinase (TIMP)-1 differed
significantly between patients who did and did not receive therapy from an
implantable cardioverter-defibrillator (ICD). Boxes represent the middle one-half
of the distribution (25th to 75th percentile). The line in a box is the median.
Figure 4 ROC Curves for Serum Collagen Markers
Performance of C-terminal telopeptide of collagen type-I (CITP), matrix metallo-
proteinase (MMP)-1, and tissue inhibitor of matrix metalloproteinase (TIMP)-1
in terms of their sensitivity and specificity. The CITP performed better than the
other 2 markers. ROC  receiver-operating characteristic.
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June 15, 2010:2753–9 Collagen Turnover and Ventricular ArrhythmiasNo significant correlation was observed between the
forementioned serum markers of collagen turnover and
VEF (r0.185, p 0.124 for CITP, r0.057, p
.64 for MMP-1, and r0.179, p 0.138 for TIMP-1).
Additionally, despite the limited patient number, for
xploratory reasons only, we performed a stepwise logistic
egression analysis, evaluating the 3 serum markers of
ollagen turnover that were univariately significant. The
esults indicate that CITP (beta  31.2, p  0.001) and
IMP-1 (beta  0.07, p  0.023) carry independent
rognostic information that should be verified in a larger
ample.
iscussion
ecause the survival benefit of ICD in NIDC patients with
oor left ventricular function has become evident after the
ublication of SCD-HeFT (Sudden Cardiac Death in
eart Failure Trial) (4), current guidelines recommend
heir implantation in this vulnerable population (5). How-
ver, the early and reliable identification of patients at
igher risk of SCD who could benefit from an ICD or,
erhaps more importantly, those who are unlikely to benefit
emains an unresolved issue.
It is a fact that, even in high-risk population groups, not
ll patients have the same risk of malignant arrhythmias. A
umber of specific techniques that detect slowed conduc-
ion, heterogeneities in ventricular repolarization, imbalance
n autonomic tone, extent of myocardial damage, and
entricular ectopy have been evaluated (16).
Although many studies have explored the value of these
echniques, the precise relationship between the presence of
hese abnormalities, some of which are persistently present,
nd the unpredictable occurrence of VT/VF has not been
lucidated (17–20). Even abnormalities in combinations of
hese techniques might fail to detect the precise pathophys-
ological abnormalities that precipitate VT or VF. Therefore
he limitations of these techniques might be due in part to
ur inadequate understanding of the milieu responsible for
nitiating clinical episodes of VT or VF.
Newer approaches that encompass a more general evalua-
ion of “vulnerability” to SCD, including serum markers,
enetic profiling, and new imaging approaches, are necessary.
The present study identifies some serum markers of
ollagen turnover as predictors of major arrhythmic events
n mild to moderate symptomatic heart failure patients due
o NIDC with LVEF 35%.
The ECM of the myocardium, which is mainly com-
osed of type I collagen fibers, plays an important role in the
emodeling process during the development of NIDC
21,22). In the normal heart, there is a balance between
ollagen synthesis by myofibroblasts and its degradation by
roteolytic enzymes (MMPs) (23). In NIDC, the fibrotic
rocess is characterized initially by degradation of properly
ross-linked type I collagen, followed by increased repara-
ive fibrosis (24). This means that altered ratios of collagen fiubtypes, pathologically produced, replace myocyte cells
hat are dead as a result of apoptosis or necrosis. The focal
ccumulation of functionally unfavorable collagen and the
egradation of relevant architecture of perimysial and en-
omysial collagen create a barrier to impulse propagation
nd interfere with conduction by impairing intermyocyte
oupling, creating an ideal arrhythmogenic substrate (25).
A number of experimental and clinical data suggest that
iochemical markers of collagen turnover correlate signifi-
antly with fibrosis in endomyocardial biopsies; thus, serum
oncentrations of procollagen propeptides can be used as
arkers of myocardial fibrosis formation or collagen degra-
ation (26–28).
In our patients, ventricular arrhythmias were associated
ith higher serum levels of CITP, a degradation marker of
ype I collagen, and this collagenolytic activity was con-
rmed by the increased concentrations of MMP-1 in the
ame patients. Furthermore, because all of our patients had
he diagnosis of NIDC for a long period, which extended
eyond the early phase of the disease, we might suppose that
he process of replacement fibrosis had started. This might
xplain the significantly increased concentration of
IMP-1, the inhibitor of collagenolysis, in patients more
rone to malignant arrhythmias.
To our knowledge, only 1 study by Blangy et al. (29)
imilarly investigated the relationship of cardiac fibrosis and
he incidence of ventricular arrhythmias—though this was
n secondary prevention ICD recipients after myocardial
nfarction—and showed that the combination of decreased
ro-collagen type III and increased pro-collagen type I was
significant marker of the risk of VT in the multivariate
nalysis.
Another interesting finding was that both CITP and
IMP-1 could provide prognostic information above and
eyond other conventional risk markers in our sample of
IDC patients, who were typical candidates for ICD
nsertion in daily clinical practice. Because all of our patients
ere under the same optimal pharmaceutical treatment and
hereas patients with sustained ventricular arrhythmias who
eceived appropriate therapy from their devices presented
ith no difference in the diameter or function of the left
entricle compared with patients without sustained arrhyth-
ias, we can speculate that the predisposition to ventricular
rrhythmias could be attributed to the fibrosis process and
ot to the presence of any confounding factor. Perhaps
urprisingly, spironolactone, which was taken by a relatively
igh proportion of patients in both groups and is known to
ffect collagen turnover (11), did not seem to affect the risk
f malignant arrhythmias. However, that could be explained
y the relatively small number of arrhythmic events and that
ur patients had mild to moderate symptomatic heart
ailure, in contrast to the severe heart failure population in
ALES (Randomized Aldactone Evaluation Study) (11).
tudy limitations. Serum markers of collagen turnover are
ot heart-specific. In addition, we did not support our
ndings with cardiac tissue biopsy data or coronary sinus
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Collagen Turnover and Ventricular Arrhythmias June 15, 2010:2753–9ampling. However, we made strenuous efforts to exclude
ubjects who had conditions associated with fibrosis.
Although the population of our study was relatively
omogenous, the relatively low VT occurrence rate would
ave necessitated a larger sample of patients with a longer
ollow-up and repeated measurements of serum markers.
ur analysis was based on a single determination of each
erum marker, which did not allow assessing for the
otential changes in these markers over time. It is possible
hat, with a longer follow-up and a larger number of events,
he predictive power of serum markers of collagen turnover
or ICD therapy could have been determined with more
recision.
Finally, because some medications for the treatment of
eart failure, such as aldosterone blockers, might alter ECM
urnover (11,30) they might have had some influence on our
atients’ outcomes. However, the medications were not
nterrupted for ethical reasons. In any case, we think that
his factor would have had a minimal effect, because all
atients were under the same optimal treatment, without
ny differences between the 2 groups. Another limitation, as
mplied in the final paragraph of the Results section, is the
otential over-fitting of the multivariate logistic regression
odel.
Given these limitations, this is the first study to estimate
he relationship between ICD shocks and serum markers of
ollagen type-I synthesis and degradation, demonstrating a
otential role for these markers in the risk of malignant
rrhythmias in patients with NIDC.
onclusions
f the maximum benefit is to be achieved from ICD therapy
n NIDC patients for the primary prevention of SCD, more
recise risk stratification is required. We observed that,
ecause ECM alterations affect the arrhythmogenic sub-
trate in NIDC, serum markers of collagen turnover could
redict arrhythmic events in ICD recipients. Although
hese results are encouraging, further large prospective
tudies are necessary to determine the positive and negative
redictive accuracy of these biomarkers and to investigate
heir predictive ability when compared with previously
etter-defined risk factors.
eprint requests and correspondence: Dr. Panos E. Vardas,
ardiology Department, Heraklion University Hospital, P.O. Box
352 Stavrakia, Heraklion, GR 711 10, Crete, Greece. E-mail:
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